This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Sage Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
De winst van Sage Therapeutics is gedaald met een gemiddeld jaarlijks percentage van -23.7%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 33.8%. De inkomsten zijn daalde met een gemiddeld percentage van 54.8% per jaar.
Belangrijke informatie
-23.65%
Groei van de winst
-22.48%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.04% |
| Inkomstengroei | -54.84% |
| Rendement op eigen vermogen | -81.68% |
| Nettomarge | -427.77% |
| Laatste winstupdate | 30 Jun 2025 |
Recente prestatie-updates uit het verleden
Recent updates
Nieuw narratief • Mar 29
Expanding ZURZUVAE Demand Will Improve Postpartum And Neuropsych Care
Establishing ZURZUVAE as the PPD care standard should drive top-line growth through increased demand and brand visibility.Seeking Alpha • Jan 22
Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid
Summary Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Its main asset is Zurzuvae, which is co-marketed with Biogen for PPD. BIIB recently made a bid for SAGE at $7.22 per share, which seems exceedingly cheap, considering SAGE has a lot of cash, and Zurzuvae is just ramping up its sales. SAGE is now contesting the takeover, which could lead to higher follow-up bids. This, I believe, adds upside optionality to the stock. Zurzuvae is also a relatively unique IP for PPD, as it has a simple 14-day regime that provides quick relief for depressive symptoms. This is why I think SAGE stock is a good buy at these levels. It seems undervalued as a standalone company or a takeover target with BIIB. Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Summary The company remains a "hold" due to Biogen's unsolicited offer to acquire shares at a 30% premium, despite pipeline setbacks. The failure of the phase 2 DIMENSION study for dalzanemdor in treating cognitive impairment in Huntington's Disease highlights Sage's shrinking pipeline. Sage's financials indicate a need for additional funding in 2025, risking dilution and further financial instability. The future of SAGE-324 and SAGE-319 remains uncertain in treating patients with neurodevelopmental disorders, adding risk to the company's long-term prospects. Read the full article on Seeking AlphaSeeking Alpha • Nov 19
CNS Drug Development: Same As It Ever Was
Summary Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling. A pivotal trial failed to show benefit, and they had several other clinical failures as well. They have a clinical trial readout in Huntington's disease later this fall, and man, that's a tough place to make your stand. Read the full article on Seeking AlphaSeeking Alpha • Oct 07
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Summary Sage Therapeutics is a "sell" due to the failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's Disease. Dalzanemdor's upcoming phase 2 studies for Huntington's and Alzheimer's diseases are unlikely to succeed, given prior trial results and similar primary endpoints. Financially, Sage has enough cash to operate until 2026, but without successful trials, raising additional funds will be challenging. Despite FDA approval of Zurzuvae for postpartum depression, it won't drive long-term growth; dalzanemdor's success is crucial for shareholder value creation. Read the full article on Seeking AlphaAnalyseartikel • Aug 30
Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge
Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders that were waiting for something to happen have been dealt a blow...Seeking Alpha • Jul 25
Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
Summary Sage Therapeutics, Inc.'s SAGE-324 failed its Phase 2b trial for essential tremor and development is discontinued. Dalzanemdor's past data in Parkinson's casts doubt on its prospects in other cognitive disorders. Zurzuvae's Q1 revenue exceeded expectations, but the market potential remains constrained by its narrow indication. Analysts are expecting $8.90 million in revenue for Q2. While Sage may exceed this, it isn't likely to move the stock much. Given clinical setbacks and limited revenue growth, I recommend downgrading Sage Therapeutics to “sell.”. Read the full article on Seeking AlphaAnalyseartikel • Jul 13
Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 7.8x Sage Therapeutics, Inc. ( NASDAQ:SAGE ) is a stock...Seeking Alpha • May 30
Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
Summary Sage Therapeutics, Inc. results from phase 2b KINETIC 2 Study, using SAGE-324 for the treatment of patients with essential tremor, expected mid-2024. Top-line data from the phase 3 SURVEYOR study, using SAGE-718 for cognitive impairment in HD patients, expected in mid-2024. Top-line data from the phase 2 DIMENSION study, using SAGE-718 for cognitive impairment in HD patients, expected late-2024. Top-line data from the phase 2 LIGHTWAVE Study, using SAGE-718 for mild cognitive impairment or mild dementia due to Alzheimer's Disease, expected late-2024. Read the full article on Seeking AlphaAnalyseartikel • May 21
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analyseartikel • Feb 22
Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
The analysts covering Sage Therapeutics, Inc. ( NASDAQ:SAGE ) delivered a dose of negativity to shareholders today, by...Analyseartikel • Feb 15
Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Key Insights Sage Therapeutics' estimated fair value is US$29.43 based on 2 Stage Free Cash Flow to Equity Sage...Seeking Alpha • Jan 22
Sizing Up Sage Therapeutics
Summary Today, we take a deeper look at Sage Therapeutics, Inc., a biopharmaceutical company focused on developing brain health medicines. The stock has fallen sharply since June on a more limited FDA approval for the company's primary drug candidate. The drug has just been launched and management has taken actions to substantially lower annual operating costs. What's ahead for Sage Therapeutics in 2024? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Aug 09
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Today is shaping up negative for Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders, with the analysts delivering a...Analyseartikel • Feb 22
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyseartikel • Nov 12
An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Today we will run through one way of estimating the intrinsic value of Sage Therapeutics, Inc. ( NASDAQ:SAGE ) by...Analyseartikel • Oct 14
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Aug 02
Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Sage Therapeutics press release (NASDAQ:SAGE): Q2 GAAP EPS of -$2.13 beats by $0.02. Revenue of $1.5M (-8.5% Y/Y) misses by $0.27M. Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2022 were $1.5 billion compared to $1.6 billion at March 31, 2022 Rolling NDA submission for zuranolone in MDD and PPD remains on track, with completion expected in the second half of 2022 Announced positive topline data from the Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD Enrolling multiple Phase 2 studies across neuropsychiatry and neurology franchises, additional trials expected to initiate throughout 2022 Cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, expected to support operations into 2025Analyseartikel • Jun 15
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Mar 24
Sage Therapeutics: Well-Funded But Uninspiring Data
Sage is well funded by Biogen. However, lead candidate SAGE-217 has not come up with strong MDD data. I continue to sit on the fence.Opbrengsten en kosten
Opbrengsten en kosten
Hoe Sage Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 25 | 70 | -301 | 227 | -88 |
| 31 Mar 25 | 47 | -354 | 221 | 0 |
| 31 Dec 24 | 41 | -401 | 216 | 0 |
| 30 Sep 24 | 106 | -338 | 217 | -4 |
| 30 Jun 24 | 97 | -446 | 242 | 0 |
| 31 Mar 24 | 91 | -503 | 261 | 0 |
| 31 Dec 23 | 86 | -541 | 275 | 0 |
| 30 Sep 23 | 11 | -656 | 287 | 20 |
| 30 Jun 23 | 10 | -592 | 270 | 0 |
| 31 Mar 23 | 9 | -558 | 247 | 0 |
| 31 Dec 22 | 8 | -533 | 228 | 0 |
| 30 Sep 22 | 6 | -510 | 212 | 0 |
| 30 Jun 22 | 6 | -503 | 199 | 0 |
| 31 Mar 22 | 6 | -484 | 190 | 0 |
| 31 Dec 21 | 6 | -458 | 183 | 0 |
| 30 Sep 21 | 1,114 | 642 | 185 | 0 |
| 30 Jun 21 | 1,114 | 666 | 172 | 0 |
| 31 Mar 21 | 1,113 | 637 | 167 | 0 |
| 31 Dec 20 | 1,114 | 606 | 197 | 0 |
| 30 Sep 20 | 7 | -537 | 229 | 0 |
| 30 Jun 20 | 9 | -612 | 282 | 0 |
| 31 Mar 20 | 9 | -644 | 332 | 0 |
| 31 Dec 19 | 7 | -680 | 346 | 0 |
| 30 Sep 19 | 5 | -670 | 336 | 0 |
| 30 Jun 19 | 2 | -613 | 302 | 0 |
| 31 Mar 19 | 91 | -462 | 256 | 0 |
| 31 Dec 18 | 90 | -373 | 201 | 0 |
| 30 Sep 18 | 90 | -284 | 145 | 0 |
| 30 Jun 18 | 90 | -235 | 108 | 0 |
| 31 Mar 18 | 0 | -288 | 79 | -45 |
| 31 Dec 17 | 0 | -270 | 63 | 0 |
| 30 Sep 17 | 0 | -257 | 58 | 42 |
| 30 Jun 17 | 0 | -221 | 51 | 71 |
| 31 Mar 17 | 0 | -185 | 45 | 142 |
| 31 Dec 16 | 0 | -159 | 39 | 0 |
| 30 Sep 16 | 0 | -132 | 33 | 99 |
| 30 Jun 16 | 0 | -118 | 31 | 88 |
| 31 Mar 16 | 0 | -108 | 28 | 80 |
| 31 Dec 15 | 0 | -94 | 25 | 69 |
| 30 Sep 15 | 0 | -78 | 20 | 58 |
| 30 Jun 15 | 0 | -64 | 17 | 47 |
| 31 Mar 15 | 0 | -47 | 12 | 33 |
| 31 Dec 14 | 0 | -36 | 10 | 24 |
Kwaliteitswinsten: SAGE is momenteel verliesgevend.
Groeiende winstmarge: SAGE is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SAGE is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 23.7% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van SAGE over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: SAGE is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 43% ).
Rendement op eigen vermogen
Hoge ROE: SAGE heeft een negatief Return on Equity ( -81.68% ), omdat het momenteel verliesgevend is.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2025/08/01 20:06 |
| Aandelenkoers aan het einde van de dag | 2025/07/30 00:00 |
| Inkomsten | 2025/06/30 |
| Jaarlijkse inkomsten | 2024/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Sage Therapeutics, Inc. wordt gevolgd door 9 analisten. 14 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Esther Lannie Hong | Berenberg |
| null null | BMO Capital Markets Equity Research |
| Gary Nachman | BMO Capital Markets Equity Research |